Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX-1502 in Plexiform Neurofibroma and Neurofibromatosis Type 1
NCT06541847Phase 2Recruiting
- Sponsor
- Healx
- Start
- Feb 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HLX-1502 in neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN), sponsored by Healx. Primary endpoint: Plexiform Neurofibroma response rate at 12 months. Started Feb 2025; status: recruiting.
02
Drugs
HLX-1502
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NCT06541847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06541847.